Related Experiment Video

Updated: Aug 25, 2026

Evaluation of Left Ventricular Structure and Function using 3D Echocardiography
06:34

Evaluation of Left Ventricular Structure and Function using 3D Echocardiography

Published on: October 28, 2020

Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left

P M Okin1, R B Devereux, J E Liu

  • 1Department of Medicine, Division of Cardiology, Weill Medical College of Cornell University, New York, NY 10021, USA. pokin@mail.med.cornell.edu

Journal of Human Hypertension
|April 2, 2004
PubMed

Insights

Changes in electrocardiogram (ECG) left ventricular hypertrophy (LVH) during treatment predict changes in LV mass. Regression of ECG LVH, particularly the Cornell product, indicates greater reduction in LV mass and anatomic LVH.

Area of Science:

  • Cardiology
  • Hypertension Management
  • Diagnostic Imaging

Background:

  • Electrocardiogram (ECG) is a common tool for detecting left ventricular hypertrophy (LVH).
  • The relationship between ECG-detected LVH changes and actual LV mass reduction during antihypertensive therapy requires clarification.

Purpose of the Study:

  • To investigate whether changes in ECG-defined LVH during antihypertensive treatment correlate with changes in echocardiographic LV mass.
  • To determine if ECG LVH regression predicts anatomic LVH regression.

Main Methods:

  • Analysis of baseline and year-1 ECG and echocardiogram data from 584 hypertensive patients in the LIFE echocardiographic substudy.
  • Patients were categorized by ECG LVH changes (regression, no significant change, progression) based on Cornell voltage-duration product criteria.
  • Echocardiographic LVH regression was defined as a ≥20% reduction in LV mass.

Main Results:

  • 27% of patients showed ECG LVH regression, 49% had no significant change, and 25% progressed after 1 year.
  • Patients with ECG LVH regression had significantly greater reductions in LV mass compared to those with no change or progression.
  • Regression of the Cornell product ECG LVH was strongly associated with greater LV mass reduction and a higher likelihood of anatomic LVH regression.

Conclusions:

  • Changes in ECG-defined LVH during antihypertensive therapy are predictive of changes in echocardiographic LV mass.
  • Regression of ECG LVH, especially using the Cornell product, signifies meaningful reduction in cardiac structural changes.
  • ECG monitoring can provide valuable insights into treatment efficacy for hypertensive patients with LVH.

More Related Videos

Histological Quantification of Chronic Myocardial Infarct in Rats09:45

Histological Quantification of Chronic Myocardial Infarct in Rats

Published on: December 11, 2016

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Mitral Regurgitation II: Clinical Features and Diagnostic Tests01:23

Mitral Regurgitation II: Clinical Features and Diagnostic Tests

Mitral regurgitation (MR) is a valvular heart disorder in which the mitral valve fails to close tightly, allowing blood to leak backward into the heart. Understanding the clinical manifestations, assessment, diagnostic findings, and medical management of MR is crucial to effectively managing affected patients.Clinical Manifestations of Mitral RegurgitationMitral regurgitation can be acute or chronic, each presenting differently and requiring different approaches:1. Acute Mitral...